메뉴 건너뛰기




Volumn 8, Issue 3, 2013, Pages 184-195

Hairy cell leukemia - New genes, new targets

Author keywords

BL22; BRAF; CD22; Dabrafenib; HCL variant; IGHV4 34; Immunotoxin; MAPK; Melanoma; Moxetumomab pasudotox; Purine analog; Recombinant immunotoxin; Trametinib; V600E; Vemurafenib

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; B RAF KINASE; CD22 ANTIGEN; CLADRIBINE; DABRAFENIB; DACARBAZINE; MITOGEN ACTIVATED PROTEIN KINASE; MOXETUMOMAB PASUDOTOX; PENTOSTATIN; RITUXIMAB; SELUMETINIB; TRAMETINIB; VEMURAFENIB; BACTERIAL TOXIN; EXOTOXIN; IMMUNOTOXIN; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; SULFONAMIDE; THYMIDINE KINASE;

EID: 84883873669     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-013-0167-0     Document Type: Article
Times cited : (20)

References (134)
  • 1
    • 0001322730 scopus 로고
    • Leukemic reticuloendotheliosis
    • 13560561 1:STN:280:DyaG1c7gtlKltQ%3D%3D
    • Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis. Blood. 1958;13:609-30.
    • (1958) Blood , vol.13 , pp. 609-630
    • Bouroncle, B.A.1    Wiseman, B.K.2    Doan, C.A.3
  • 3
    • 84875804295 scopus 로고    scopus 로고
    • Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
    • 23485231 1:STN:280:DC%2BC3svlsVantg%3D%3D 10.1016/j.ejca.2012.12.027
    • Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374-403.
    • (2013) Eur J Cancer , vol.49 , pp. 1374-1403
    • Ferlay, J.1    Steliarova-Foucher, E.2    Lortet-Tieulent, J.3    Rosso, S.4    Coebergh, J.W.5    Comber, H.6
  • 4
    • 0028344716 scopus 로고
    • Hairy cell leukemia: A clinical review based on 725 cases of the Italian Cooperative Group (ICGHCL). Italian Cooperative Group for Hairy Cell Leukemia
    • 7519510 1:STN:280:DyaK2czisFygug%3D%3D 10.3109/10428199409056295
    • Frassoldati A, Lamparelli T, Federico M, Annino L, Capnist G, Pagnucco G, et al. Hairy cell leukemia: a clinical review based on 725 cases of the Italian Cooperative Group (ICGHCL). Italian Cooperative Group for Hairy Cell Leukemia. Leuk Lymphoma. 1994;13:307-16.
    • (1994) Leuk Lymphoma , vol.13 , pp. 307-316
    • Frassoldati, A.1    Lamparelli, T.2    Federico, M.3    Annino, L.4    Capnist, G.5    Pagnucco, G.6
  • 5
    • 0018342203 scopus 로고
    • Leukemic reticuloendotheliosis (hairy cell leukemia)
    • 367468 1:STN:280:DyaE1M7gsVanug%3D%3D
    • Bouroncle BA. Leukemic reticuloendotheliosis (hairy cell leukemia). Blood. 1979;53:412-36.
    • (1979) Blood , vol.53 , pp. 412-436
    • Bouroncle, B.A.1
  • 6
    • 33748616255 scopus 로고    scopus 로고
    • Clinical presentations and complications of hairy cell leukemia
    • 16990107 10.1016/j.hoc.2006.06.003
    • Hoffman MA. Clinical presentations and complications of hairy cell leukemia. Hematol Oncol Clin North Am. 2006;20:1065-73.
    • (2006) Hematol Oncol Clin North Am , vol.20 , pp. 1065-1073
    • Hoffman, M.A.1
  • 7
    • 0029028995 scopus 로고
    • Disease-related hypocholesterolemia in patients with hairy cell leukemia. Positive correlation with spleen size but not with tumor cell burden or low density lipoprotein receptor activity
    • 8625123 1:STN:280:DyaK283itlSntA%3D%3D 10.1002/1097-0142(19950801)76: 3<423: AID-CNCR2820760312>3.0.CO;2-T
    • Juliusson G, Vitols S, Liliemark J. Disease-related hypocholesterolemia in patients with hairy cell leukemia. Positive correlation with spleen size but not with tumor cell burden or low density lipoprotein receptor activity. Cancer. 1995;76:423-8.
    • (1995) Cancer , vol.76 , pp. 423-428
    • Juliusson, G.1    Vitols, S.2    Liliemark, J.3
  • 8
    • 0027989718 scopus 로고
    • Thirty-five years in the progress of hairy cell leukemia
    • 7820038
    • Bouroncle BA. Thirty-five years in the progress of hairy cell leukemia. Leuk Lymphoma. 1994;14 Suppl 1:1-12.
    • (1994) Leuk Lymphoma , vol.14 , Issue.SUPPL. 1 , pp. 1-12
    • Bouroncle, B.A.1
  • 9
    • 0037247093 scopus 로고    scopus 로고
    • The variant form of hairy-cell leukaemia
    • 12670464 1:CAS:528:DC%2BD3sXisFSnsL0%3D 10.1016/S1521-6926(02)00086-5
    • Matutes E, Wotherspoon A, Catovsky D. The variant form of hairy-cell leukaemia. Best Pract Res Clin Haematol. 2003;16:41-56.
    • (2003) Best Pract Res Clin Haematol , vol.16 , pp. 41-56
    • Matutes, E.1    Wotherspoon, A.2    Catovsky, D.3
  • 10
    • 0027963527 scopus 로고
    • The immunophenotype of hairy cell leukemia (HCL). Proposal for a scoring system to distinguish HCL from B cell disorders with hairy or villous lymphocytes
    • 7820054
    • Matutes E, Morilla R, Owusu-Ankomah K, Houliham A, Meeus P, Catovsky D. The immunophenotype of hairy cell leukemia (HCL). Proposal for a scoring system to distinguish HCL from B cell disorders with hairy or villous lymphocytes. Leuk Lymphoma. 1994;14(1):57-61.
    • (1994) Leuk Lymphoma , vol.14 , Issue.1 , pp. 57-61
    • Matutes, E.1    Morilla, R.2    Owusu-Ankomah, K.3    Houliham, A.4    Meeus, P.5    Catovsky, D.6
  • 11
    • 0027247855 scopus 로고
    • Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia
    • 7688993 1:STN:280:DyaK3szlslCrtw%3D%3D
    • Robbins BA, Ellison DJ, Spinosa JC, Carey CA, Lukes RJ, Poppema S, et al. Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia. Blood. 1993;82:1277-87.
    • (1993) Blood , vol.82 , pp. 1277-1287
    • Robbins, B.A.1    Ellison, D.J.2    Spinosa, J.C.3    Carey, C.A.4    Lukes, R.J.5    Poppema, S.6
  • 12
    • 80053532947 scopus 로고    scopus 로고
    • Characteristic CD103 and CD123 Expression Pattern Defines Hairy Cell Leukemia: Usefulness of CD123 and CD103 in the Diagnosis of Mature B cell Lymphoproliferative Disorders
    • 21917686 10.1309/AJCPKUM9J4IXCWEU
    • Venkataraman G, Aguhar C, Kreitman RJ, Yuan CM, Stetler-Stevenson M. Characteristic CD103 and CD123 Expression Pattern Defines Hairy Cell Leukemia: Usefulness of CD123 and CD103 in the Diagnosis of Mature B cell Lymphoproliferative Disorders. Am J Clin Pathol. 2011;136:625-30.
    • (2011) Am J Clin Pathol , vol.136 , pp. 625-630
    • Venkataraman, G.1    Aguhar, C.2    Kreitman, R.J.3    Yuan, C.M.4    Stetler-Stevenson, M.5
  • 14
    • 84875382111 scopus 로고    scopus 로고
    • Distinguishing Hairy Cell Leukemia Variant from Hairy Cell Leukemia: Development and Validation of Diagnostic Criteria
    • 10.1016/j.leukres.2012.11.021 1:CAS:528:DC%2BC3sXhs1ersrg%3D
    • Shao H, Calvo KR, Grönborg M, Tembhare PR, Kreitman RJ, Stetler-Stevenson M, et al. Distinguishing Hairy Cell Leukemia Variant from Hairy Cell Leukemia: Development and Validation of Diagnostic Criteria. Leuk Res. 2012;37:401-9.
    • (2012) Leuk Res , vol.37 , pp. 401-409
    • Shao, H.1    Calvo, K.R.2    Grönborg, M.3    Tembhare, P.R.4    Kreitman, R.J.5    Stetler-Stevenson, M.6
  • 15
    • 33748780373 scopus 로고    scopus 로고
    • The pathophysiology of the hairy cell
    • 16990104 1:STN:280:DC%2BD28rmsVOisA%3D%3D 10.1016/j.hoc.2006.06.002
    • Cawley JC. The pathophysiology of the hairy cell. Hematol Oncol Clin North Am. 2006;20:1011-21.
    • (2006) Hematol Oncol Clin North Am , vol.20 , pp. 1011-1021
    • Cawley, J.C.1
  • 16
    • 46749133998 scopus 로고    scopus 로고
    • Reaction patterns of TRAP and DBA.44 in hairy cell leukemia, hairy cell variant, and nodal and extranodal marginal zone B cell lymphomas
    • 18227730 10.1097/PAI.0b013e3180471fd4
    • Dunphy CH. Reaction patterns of TRAP and DBA.44 in hairy cell leukemia, hairy cell variant, and nodal and extranodal marginal zone B cell lymphomas. Appl Immunohistochem Mol Morphol. 2008;16:135-9.
    • (2008) Appl Immunohistochem Mol Morphol , vol.16 , pp. 135-139
    • Dunphy, C.H.1
  • 17
    • 2942622200 scopus 로고    scopus 로고
    • Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1)
    • 15183626 1:CAS:528:DC%2BD2cXks1ert70%3D 10.1016/S0140-6736(04)16356-3
    • Falini B, Tiacci E, Liso A, Basso K, Sabattini E, Pacini R, et al. Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). Lancet. 2004;363:1869-70.
    • (2004) Lancet , vol.363 , pp. 1869-1870
    • Falini, B.1    Tiacci, E.2    Liso, A.3    Basso, K.4    Sabattini, E.5    Pacini, R.6
  • 18
    • 0019120145 scopus 로고
    • A chronic lymphoproliferative disorder with distinctive features: A distinct variant of hairy-cell leukaemia
    • 7206776 1:STN:280:DyaL3M7kslSnsQ%3D%3D 10.1016/0145-2126(80)90066-1
    • Cawley JC, Burns GF, Hayhoe FG. A chronic lymphoproliferative disorder with distinctive features: a distinct variant of hairy-cell leukaemia. Leuk Res. 1980;4:547-59.
    • (1980) Leuk Res , vol.4 , pp. 547-559
    • Cawley, J.C.1    Burns, G.F.2    Hayhoe, F.G.3
  • 19
    • 0035141123 scopus 로고    scopus 로고
    • The natural history and clinico-pathological features of the variant form of hairy cell leukemia
    • 11243388 1:STN:280:DC%2BD3M7nsl2gtg%3D%3D 10.1038/sj.leu.2401999
    • Matutes E, Wotherspoon A, Brito-Babapulle V, Catovsky D. The natural history and clinico-pathological features of the variant form of hairy cell leukemia. Leukemia. 2001;15:184-6.
    • (2001) Leukemia , vol.15 , pp. 184-186
    • Matutes, E.1    Wotherspoon, A.2    Brito-Babapulle, V.3    Catovsky, D.4
  • 20
    • 0037764931 scopus 로고    scopus 로고
    • Hairy cell leukemia: Biology, clinical diagnosis, unusual manifestations and associated disorders
    • 12823778 10.1046/j.1468-0734.2002.00304.x discussion 449-50
    • Polliack A. Hairy cell leukemia: Biology, clinical diagnosis, unusual manifestations and associated disorders. Rev Clin Exp Hematol. 2002;6:366-88. discussion 449-50.
    • (2002) Rev Clin Exp Hematol , vol.6 , pp. 366-388
    • Polliack, A.1
  • 21
    • 40749143143 scopus 로고    scopus 로고
    • Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria
    • 18094718 1:STN:280:DC%2BD1c7nsVKrsQ%3D%3D 10.1038/sj.leu.2405068
    • Matutes E, Oscier D, Montalban C, Berger F, CalletBauchu E, Dogan A, et al. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia. 2008;22:487-95.
    • (2008) Leukemia , vol.22 , pp. 487-495
    • Matutes, E.1    Oscier, D.2    Montalban, C.3    Berger, F.4    Calletbauchu, E.5    Dogan, A.6
  • 22
    • 73949120281 scopus 로고    scopus 로고
    • VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy
    • 19745070 1:CAS:528:DC%2BD1MXhsFWitrvM 10.1182/blood-2009-01-201731
    • Arons E, Suntum T, Stetler-Stevenson M, Kreitman RJ. VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood. 2009;114:4687-95.
    • (2009) Blood , vol.114 , pp. 4687-4695
    • Arons, E.1    Suntum, T.2    Stetler-Stevenson, M.3    Kreitman, R.J.4
  • 23
    • 0021345092 scopus 로고
    • Alpha interferon for induction of remission in hairy-cell leukemia
    • 6689734 1:STN:280:DyaL2c%2FmvVSqsw%3D%3D 10.1056/NEJM198401053100104
    • Quesada JR, Reuben J, Manning JT, Hersh EM, Gutterman JU. Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med. 1984;310:15-8.
    • (1984) N Engl J Med , vol.310 , pp. 15-18
    • Quesada, J.R.1    Reuben, J.2    Manning, J.T.3    Hersh, E.M.4    Gutterman, J.U.5
  • 24
    • 33748614085 scopus 로고    scopus 로고
    • Splenectomy, interferon, and treatments of historical interest in hairy cell leukemia
    • 16990108 10.1016/j.hoc.2006.06.006
    • Habermann TM. Splenectomy, interferon, and treatments of historical interest in hairy cell leukemia. Hematol Oncol Clin North Am. 2006;20:1075-86.
    • (2006) Hematol Oncol Clin North Am , vol.20 , pp. 1075-1086
    • Habermann, T.M.1
  • 25
    • 0028929938 scopus 로고
    • Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: An intergroup study
    • 7707126 1:STN:280:DyaK2M3it1ehug%3D%3D
    • Grever M, Kopecky K, Foucar MK, Head D, Bennett JM, Hutchison RE, et al. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol. 1995;13:974-82.
    • (1995) J Clin Oncol , vol.13 , pp. 974-982
    • Grever, M.1    Kopecky, K.2    Foucar, M.K.3    Head, D.4    Bennett, J.M.5    Hutchison, R.E.6
  • 26
    • 0034329819 scopus 로고    scopus 로고
    • Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin
    • 11049974 1:CAS:528:DC%2BD3cXnslGnsbg%3D
    • Flinn IW, Kopecky KJ, Foucar MK, Head D, Bennett JM, Huchison R, et al. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood. 2000;96:2981-6.
    • (2000) Blood , vol.96 , pp. 2981-2986
    • Flinn, I.W.1    Kopecky, K.J.2    Foucar, M.K.3    Head, D.4    Bennett, J.M.5    Huchison, R.6
  • 27
    • 0024590995 scopus 로고
    • Pentostatin in the treatment of advanced hairy cell leukemia
    • 2783731 1:STN:280:DyaL1M7isFShsw%3D%3D
    • Kraut EH, Bouroncle BA, Grever MR. Pentostatin in the treatment of advanced hairy cell leukemia. J Clin Oncol. 1989;7:168-72.
    • (1989) J Clin Oncol , vol.7 , pp. 168-172
    • Kraut, E.H.1    Bouroncle, B.A.2    Grever, M.R.3
  • 28
    • 0033919638 scopus 로고    scopus 로고
    • Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): A National Cancer Institute of Canada Study
    • 10877049 1:CAS:528:DC%2BD3cXksVCns74%3D
    • Johnston JB, Eisenhauer E, Wainman N, Corbett WEN, Zaentz SD, Daeninck P. Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): A National Cancer Institute of Canada Study. Semin Oncol. 2000;27:32-6.
    • (2000) Semin Oncol , vol.27 , pp. 32-36
    • Johnston, J.B.1    Eisenhauer, E.2    Wainman, N.3    Corbett, W.E.N.4    Zaentz, S.D.5    Daeninck, P.6
  • 29
    • 0034650780 scopus 로고    scopus 로고
    • Deoxycoformycin in the treatment of patients with hairy cell leukemia: Results of a Spanish collaborative study of 80 patients
    • 10640967 1:CAS:528:DC%2BD3cXpt1Cntw%3D%3D 10.1002/(SICI)1097- 0142(20000115)88:2<352: AID-CNCR15>3.0.CO;2-8
    • Rafel M, Cervantes F, Beltran JM, Zuazu F, Hernandez Nieto L, Rayon C, et al. Deoxycoformycin in the treatment of patients with hairy cell leukemia: results of a Spanish collaborative study of 80 patients. Cancer. 2000;88:352-7.
    • (2000) Cancer , vol.88 , pp. 352-357
    • Rafel, M.1    Cervantes, F.2    Beltran, J.M.3    Zuazu, F.4    Hernandez Nieto, L.5    Rayon, C.6
  • 30
    • 0037269178 scopus 로고    scopus 로고
    • Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients
    • 12529659 1:CAS:528:DC%2BD3sXjsFyktA%3D%3D 10.1038/sj.leu.2402784
    • Maloisel F, Benboubker L, Gardembas M, Coiffier B, Divine M, Sebban C, et al. Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients. Leukemia. 2003;17:45-51.
    • (2003) Leukemia , vol.17 , pp. 45-51
    • Maloisel, F.1    Benboubker, L.2    Gardembas, M.3    Coiffier, B.4    Divine, M.5    Sebban, C.6
  • 31
    • 28044446541 scopus 로고    scopus 로고
    • Long remissions in hairy cell leukemia with purine analogs - A report of 219 patients with a median follow-up of 12.5 years
    • 16245328 1:CAS:528:DC%2BD2MXhtlWgt7bL 10.1002/cncr.21447
    • Else M, Ruchlemer R, Osuji N, DelGiudice I, Matutes E, Woodman A, et al. Long remissions in hairy cell leukemia with purine analogs - A report of 219 patients with a median follow-up of 12.5 years. Cancer. 2005;104:2442-8.
    • (2005) Cancer , vol.104 , pp. 2442-2448
    • Else, M.1    Ruchlemer, R.2    Osuji, N.3    Delgiudice, I.4    Matutes, E.5    Woodman, A.6
  • 32
    • 0025274664 scopus 로고
    • Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine
    • 1969613 1:STN:280:DyaK3c3gs1SjsQ%3D%3D 10.1056/NEJM199004193221605
    • Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med. 1990;322:1117-21.
    • (1990) N Engl J Med , vol.322 , pp. 1117-1121
    • Piro, L.D.1    Carrera, C.J.2    Carson, D.A.3    Beutler, E.4
  • 33
    • 0032530684 scopus 로고    scopus 로고
    • Long-term follow-up of patients with hairy cell leukemia after cladribine treatment
    • 9731048 1:CAS:528:DyaK1cXmtVOhtbw%3D
    • Saven A, Burian C, Koziol JA, Piro LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood. 1998;92:1918-26.
    • (1998) Blood , vol.92 , pp. 1918-1926
    • Saven, A.1    Burian, C.2    Koziol, J.A.3    Piro, L.D.4
  • 34
    • 0037362951 scopus 로고    scopus 로고
    • Extended follow-up of patients with hairy cell leukemia after treatment with cladribine
    • 12610190 10.1200/JCO.2003.05.093
    • Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol. 2003;21:891-6.
    • (2003) J Clin Oncol , vol.21 , pp. 891-896
    • Goodman, G.R.1    Burian, C.2    Koziol, J.A.3    Saven, A.4
  • 35
    • 0031670669 scopus 로고    scopus 로고
    • Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: A report of 979 patients
    • 9738569 1:CAS:528:DyaK1cXmtFSlsL4%3D
    • Cheson BD, Sorensen JM, Vena DA, Montello MJ, Barrett JA, Damasio E, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients. J Clin Oncol. 1998;16:3007-15.
    • (1998) J Clin Oncol , vol.16 , pp. 3007-3015
    • Cheson, B.D.1    Sorensen, J.M.2    Vena, D.A.3    Montello, M.J.4    Barrett, J.A.5    Damasio, E.6
  • 36
    • 15844406220 scopus 로고    scopus 로고
    • 2-chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia
    • 8724536 1:STN:280:DyaK28zjtV2iuw%3D%3D 10.3109/10428199609051736
    • Robak T, Blasinska-Morawiec M, Krykowski E, Hansz J, Komarnicki M, Kazimierczak M, et al. 2-chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia. Leuk Lymphoma. 1996;22:107-11.
    • (1996) Leuk Lymphoma , vol.22 , pp. 107-111
    • Robak, T.1    Blasinska-Morawiec, M.2    Krykowski, E.3    Hansz, J.4    Komarnicki, M.5    Kazimierczak, M.6
  • 37
    • 0036809024 scopus 로고    scopus 로고
    • Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: A phase II study
    • 10.1093/annonc/mdf272
    • von Rohr A, Schmitz SF, Tichelli A, Hess U, Piguet D, Wernli M, et al. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study. Ann Oncol. 2002;13:1641-9.
    • (2002) Ann Oncol , vol.13 , pp. 1641-1649
    • Von Rohr, A.1    Schmitz, S.F.2    Tichelli, A.3    Hess, U.4    Piguet, D.5    Wernli, M.6
  • 38
    • 0028925970 scopus 로고
    • Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia
    • 7707128 1:STN:280:DyaK2M3it1egsg%3D%3D
    • Juliusson G, Heldal D, Hippe E, Hedenus M, Malm C, Wallman K, et al. Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. J Clin Oncol. 1995;13:989-95.
    • (1995) J Clin Oncol , vol.13 , pp. 989-995
    • Juliusson, G.1    Heldal, D.2    Hippe, E.3    Hedenus, M.4    Malm, C.5    Wallman, K.6
  • 39
    • 0033949050 scopus 로고    scopus 로고
    • Pharmacokinetics of 2-chloro-2 '-deoxyadenosine administered subcutaneously or by continuous intravenous infusion
    • 10912576 1:CAS:528:DC%2BD3cXjvVKisrc%3D 10.1007/s002800000129
    • Sonderegger T, Betticher DC, Cerny T, Lauterburg BH. Pharmacokinetics of 2-chloro-2 '-deoxyadenosine administered subcutaneously or by continuous intravenous infusion. Cancer Chemother Pharmacol. 2000;46:40-2.
    • (2000) Cancer Chemother Pharmacol , vol.46 , pp. 40-42
    • Sonderegger, T.1    Betticher, D.C.2    Cerny, T.3    Lauterburg, B.H.4
  • 40
    • 0031914636 scopus 로고    scopus 로고
    • Five day intermittent vs. Seven day continuous 2-chlorodeoxyadenosine infusion for the treatment of hairy cell leukemia. A study by Italian Group for the Hairy Cell Leukemia
    • 9558908 1:STN:280:DyaK1c3hvFKiuw%3D%3D
    • Damasio EE, Resegotti L, Masoudi B, Bruni R, Cerri R, Isaza A, et al. Five day intermittent vs. seven day continuous 2-chlorodeoxyadenosine infusion for the treatment of hairy cell leukemia. A study by Italian Group for the Hairy Cell Leukemia. Recenti Prog Med. 1998;89:68-73.
    • (1998) Recenti Prog Med , vol.89 , pp. 68-73
    • Damasio, E.E.1    Resegotti, L.2    Masoudi, B.3    Bruni, R.4    Cerri, R.5    Isaza, A.6
  • 41
    • 0032932661 scopus 로고    scopus 로고
    • 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland
    • 9918312 1:CAS:528:DyaK1MXlt1Slsg%3D%3D 10.1111/j.1600-0609.1999.tb01114.x
    • Robak T, Blasinska-Morawiec M, Blonski J, Hellmann A, Halaburda K, Konopka L, et al. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland. Eur J Haematol. 1999;62:49-56.
    • (1999) Eur J Haematol , vol.62 , pp. 49-56
    • Robak, T.1    Blasinska-Morawiec, M.2    Blonski, J.3    Hellmann, A.4    Halaburda, K.5    Konopka, L.6
  • 42
    • 0032725388 scopus 로고    scopus 로고
    • Treatment of hairy cell leukemia-variant with cladribine
    • 10706459 1:CAS:528:DC%2BD3MXlvFCq 10.3109/10428199909145739
    • Tetreault SA, Robbins BA, Saven A. Treatment of hairy cell leukemia-variant with cladribine. Leuk Lymphoma. 1999;35:347-54.
    • (1999) Leuk Lymphoma , vol.35 , pp. 347-354
    • Tetreault, S.A.1    Robbins, B.A.2    Saven, A.3
  • 43
    • 27644449231 scopus 로고    scopus 로고
    • Phase II clinical study of cladribine in the treatment of hairy cell leukemia
    • 16207596 1:CAS:528:DC%2BD2MXht1ehsLvP 10.1532/IJH97.04128
    • Machii T, Chou T, Suzuki M, Ohe Y, Katagiri S, Kitano EK, et al. Phase II clinical study of cladribine in the treatment of hairy cell leukemia. Int J Hematol. 2005;82:230-5.
    • (2005) Int J Hematol , vol.82 , pp. 230-235
    • Machii, T.1    Chou, T.2    Suzuki, M.3    Ohe, Y.4    Katagiri, S.5    Kitano, E.K.6
  • 44
    • 0036154475 scopus 로고    scopus 로고
    • Cladribine (2-chlorodeoxyadenosine) therapy in hairy cell leukemia variant. A report of three cases
    • 11801472
    • Palomera L, Domingo JM, Sola C, Azaceta G, Calvo MT, Gutierrez M. Cladribine (2-chlorodeoxyadenosine) therapy in hairy cell leukemia variant. A report of three cases. Haematologica. 2002;87:107-8.
    • (2002) Haematologica , vol.87 , pp. 107-108
    • Palomera, L.1    Domingo, J.M.2    Sola, C.3    Azaceta, G.4    Calvo, M.T.5    Gutierrez, M.6
  • 45
    • 79954608457 scopus 로고    scopus 로고
    • Commentary on the WHO classification of tumors of lymphoid tissues (2008): Indolent B cell lymphomas
    • 19669189 10.1007/s12308-009-0037-9
    • Ott G, Balague-Ponz O, de Leval L, de Jong D, Hasserjian RP, Elenitoba-Johnson KS. Commentary on the WHO classification of tumors of lymphoid tissues (2008): indolent B cell lymphomas. J Hematop. 2009;2:77-81.
    • (2009) J Hematop , vol.2 , pp. 77-81
    • Ott, G.1    Balague-Ponz, O.2    De Leval, L.3    De Jong, D.4    Hasserjian, R.P.5    Elenitoba-Johnson, K.S.6
  • 47
    • 66749169284 scopus 로고    scopus 로고
    • Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis
    • 19344416 1:CAS:528:DC%2BD1MXosVart7c%3D 10.1111/j.1365-2141.2009.07668.x
    • Else M, Dearden CE, Matutes E, Garcia-Talavera J, Rohatiner AZ, Johnson SA, et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol. 2009;145:733-40.
    • (2009) Br J Haematol , vol.145 , pp. 733-740
    • Else, M.1    Dearden, C.E.2    Matutes, E.3    Garcia-Talavera, J.4    Rohatiner, A.Z.5    Johnson, S.A.6
  • 48
    • 77950398474 scopus 로고    scopus 로고
    • Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine
    • 20056789 1:CAS:528:DC%2BC3cXhtFensbnJ 10.1182/blood-2009-10-251645
    • Sigal DS, Sharpe R, Burian C, Saven A. Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine. Blood. 2010;115:1893-6.
    • (2010) Blood , vol.115 , pp. 1893-1896
    • Sigal, D.S.1    Sharpe, R.2    Burian, C.3    Saven, A.4
  • 49
    • 0028289425 scopus 로고
    • 2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia
    • 7910051 1:CAS:528:DyaK2cXlt1Cksrk%3D
    • Seymour JF, Kurzrock R, Freireich EJ, Estey EH. 2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood. 1994;83:2906-11.
    • (1994) Blood , vol.83 , pp. 2906-2911
    • Seymour, J.F.1    Kurzrock, R.2    Freireich, E.J.3    Estey, E.H.4
  • 50
    • 0031052623 scopus 로고    scopus 로고
    • Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7- year follow-up
    • 9001417 1:CAS:528:DyaK2sXnsV2hs7Y%3D 10.1038/sj.leu.2400513
    • Seymour JF, Talpaz M, Kurzrock R. Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7- year follow-up. Leukemia. 1997;11:42-7.
    • (1997) Leukemia , vol.11 , pp. 42-47
    • Seymour, J.F.1    Talpaz, M.2    Kurzrock, R.3
  • 51
    • 0027999381 scopus 로고
    • Neurotoxicity of purine analogs: A review
    • 7931492 1:STN:280:DyaK2M%2Fhs1yruw%3D%3D
    • Cheson BD, Vena DA, Foss FM, Sorensen JM. Neurotoxicity of purine analogs: A review. J Clin Oncol. 1994;12:2216-28.
    • (1994) J Clin Oncol , vol.12 , pp. 2216-2228
    • Cheson, B.D.1    Vena, D.A.2    Foss, F.M.3    Sorensen, J.M.4
  • 52
    • 0042236345 scopus 로고    scopus 로고
    • Mechanism of action and resistance to monoclonal antibody therapy
    • 12939711 1:CAS:528:DC%2BD3sXntl2msbw%3D 10.1016/S0093-7754(03)00261-6
    • Villamor N, Montserrat E, Colomer D. Mechanism of action and resistance to monoclonal antibody therapy. Semin Oncol. 2003;30:424-33.
    • (2003) Semin Oncol , vol.30 , pp. 424-433
    • Villamor, N.1    Montserrat, E.2    Colomer, D.3
  • 54
    • 0032832588 scopus 로고    scopus 로고
    • Chimeric monoclonal anti-CD20 antibody (rituximab)-an effective treatment for a patient with relapsing hairy cell leukaemia
    • 10523804 1:STN:280:DyaK1Mvls1egsw%3D%3D 10.1007/BF02906136
    • Hagberg H. Chimeric monoclonal anti-CD20 antibody (rituximab)-an effective treatment for a patient with relapsing hairy cell leukaemia. Med Oncol. 1999;16:221-2.
    • (1999) Med Oncol , vol.16 , pp. 221-222
    • Hagberg, H.1
  • 55
    • 0033855944 scopus 로고    scopus 로고
    • Bone marrow remission of hairy cell leukaemia induced by rituximab (anti-CD20 monoclonal antibody) in a patient refractory to cladribine
    • 10970137 1:STN:280:DC%2BD3cvgvFWnsA%3D%3D 10.1046/j.1365-2141.2000. 109004900.x
    • Hoffman M, Auerbach L. Bone marrow remission of hairy cell leukaemia induced by rituximab (anti-CD20 monoclonal antibody) in a patient refractory to cladribine. Br J Haematol. 2000;109:900-1.
    • (2000) Br J Haematol , vol.109 , pp. 900-901
    • Hoffman, M.1    Auerbach, L.2
  • 56
    • 0742287902 scopus 로고    scopus 로고
    • Simultaneous manifestation of chronic lymphocytic leukemia (CLL) and hairy cell leukemia (HCL)
    • 14755378 10.1002/ajh.10459
    • Sokol L, Agosti SJ. Simultaneous manifestation of chronic lymphocytic leukemia (CLL) and hairy cell leukemia (HCL). American Journal of Hematology. 2004;75:107-9.
    • (2004) American Journal of Hematology , vol.75 , pp. 107-109
    • Sokol, L.1    Agosti, S.J.2
  • 57
    • 0036959124 scopus 로고    scopus 로고
    • Rituximab: A useful drug for a repeatedly relapsed hairy cell leukemia patient
    • 12483372 1:STN:280:DC%2BD38jitVakug%3D%3D 10.1007/s00277-002-0559-z
    • Pollio F, Pocali B, Palmieri S, Morabito P, Scalia G, Del Vecchio L, et al. Rituximab: a useful drug for a repeatedly relapsed hairy cell leukemia patient. Ann Hematol. 2002;81:736-8.
    • (2002) Ann Hematol , vol.81 , pp. 736-738
    • Pollio, F.1    Pocali, B.2    Palmieri, S.3    Morabito, P.4    Scalia, G.5    Del Vecchio, L.6
  • 58
    • 0035669026 scopus 로고    scopus 로고
    • Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia
    • 11736943 1:CAS:528:DC%2BD38XnsVWruw%3D%3D 10.1046/j.1365-2141.2001.03143. x
    • Hagberg H, Lundholm L. Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia. Br J Haematol. 2001;115:609-11.
    • (2001) Br J Haematol , vol.115 , pp. 609-611
    • Hagberg, H.1    Lundholm, L.2
  • 59
    • 0034766754 scopus 로고    scopus 로고
    • Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia
    • 11602410 1:CAS:528:DC%2BD3MXptVKktb0%3D
    • Lauria F, Lenoci M, Annino L, Raspadori D, Marotta G, Bocchia M, et al. Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia. Haematologica. 2001;86:1046-50.
    • (2001) Haematologica , vol.86 , pp. 1046-1050
    • Lauria, F.1    Lenoci, M.2    Annino, L.3    Raspadori, D.4    Marotta, G.5    Bocchia, M.6
  • 60
    • 0042243678 scopus 로고    scopus 로고
    • Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia
    • 12663446 1:CAS:528:DC%2BD3sXlvFCmsLw%3D 10.1182/blood-2003-01-0014
    • Nieva J, Bethel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood. 2003;102:810-3.
    • (2003) Blood , vol.102 , pp. 810-813
    • Nieva, J.1    Bethel, K.2    Saven, A.3
  • 61
    • 0345689335 scopus 로고    scopus 로고
    • Rituximab in relapsed or refractory hairy cell leukemia
    • 12816862 1:CAS:528:DC%2BD3sXpsFamurk%3D 10.1182/blood-2003-02-0630
    • Thomas DA, O'Brien S, Bueso-Ramos C, Faderl S, Keating MJ, Giles FJ, et al. Rituximab in relapsed or refractory hairy cell leukemia. Blood. 2003;102:3906-11.
    • (2003) Blood , vol.102 , pp. 3906-3911
    • Thomas, D.A.1    O'Brien, S.2    Bueso-Ramos, C.3    Faderl, S.4    Keating, M.J.5    Giles, F.J.6
  • 62
  • 63
    • 50849088318 scopus 로고    scopus 로고
    • Rituximab in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine (SAKK 31/98)
    • 1:CAS:528:DC%2BD1cXhtl2gur%2FJ 10.3324/haematol.11564
    • Zenhausern R, Simcock M, Gratwohl A, Hess U, Bargetzi M, Tobler A. Rituximab in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine (SAKK 31/98). Haematol Hematol J. 2008;93:1426-8.
    • (2008) Haematol Hematol J , vol.93 , pp. 1426-1428
    • Zenhausern, R.1    Simcock, M.2    Gratwohl, A.3    Hess, U.4    Bargetzi, M.5    Tobler, A.6
  • 64
    • 5444223561 scopus 로고    scopus 로고
    • Alemtuzumab (Campath 1H) in hairy cell leukaemia relapsing after rituximab treatment
    • 15448675 1:CAS:528:DC%2BD2cXnvVKms70%3D 10.1038/sj.thj.6200373
    • Fietz T, Rieger K, Schmittel A, Thiel E, Knauf W. Alemtuzumab (Campath 1H) in hairy cell leukaemia relapsing after rituximab treatment. Hematol J. 2004;5:451-2.
    • (2004) Hematol J , vol.5 , pp. 451-452
    • Fietz, T.1    Rieger, K.2    Schmittel, A.3    Thiel, E.4    Knauf, W.5
  • 65
    • 0344443814 scopus 로고    scopus 로고
    • CD52 expression in hairy cell leukemia
    • 14635201 1:CAS:528:DC%2BD2cXhtlaitQ%3D%3D 10.1002/ajh.10428
    • Quigley MM, Bethel KJ, Sharpe RW, Saven A. CD52 expression in hairy cell leukemia. Am J Hematol. 2003;74:227-30.
    • (2003) Am J Hematol , vol.74 , pp. 227-230
    • Quigley, M.M.1    Bethel, K.J.2    Sharpe, R.W.3    Saven, A.4
  • 66
    • 0023664263 scopus 로고
    • The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes
    • 3571242 1:CAS:528:DyaL2sXhvFSku74%3D
    • Endo Y, Mitsui K, Motizuki M, Tsurugi K. The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. J Biol Chem. 1987;262:5908-12.
    • (1987) J. Biol. Chem. , vol.262 , pp. 5908-5912
    • Endo, Y.1    Mitsui, K.2    Motizuki, M.3    Tsurugi, K.4
  • 67
    • 0019309042 scopus 로고
    • Entry of lethal doses of abrin, ricin and modeccin into the cytosol of HeLa cells
    • 7363949 1:CAS:528:DyaL3cXktl2jt7w%3D 10.1016/0014-4827(80)90270-0
    • Eiklid K, Olsnes S, Pihl A. Entry of lethal doses of abrin, ricin and modeccin into the cytosol of HeLa cells. Exp Cell Res. 1980;126:321-6.
    • (1980) Exp. Cell Res. , vol.126 , pp. 321-326
    • Eiklid, K.1    Olsnes, S.2    Pihl, A.3
  • 68
    • 0018167496 scopus 로고
    • One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell
    • 699044 1:CAS:528:DyaE1cXlvFaitrc%3D 10.1016/0092-8674(78)90099-5
    • Yamaizumi M, Mekada E, Uchida T, Okada Y. One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell. 1978;15:245-50.
    • (1978) Cell , vol.15 , pp. 245-250
    • Yamaizumi, M.1    Mekada, E.2    Uchida, T.3    Okada, Y.4
  • 69
    • 0030830611 scopus 로고    scopus 로고
    • Getting plant toxins to fuse
    • 1:STN:280:DyaK1c%2Fms1Oitg%3D%3D 10.1016/S0145-2126(97)00083-0
    • Kreitman RJ. Getting plant toxins to fuse. Leukemia Res. 1997;21:997-9.
    • (1997) Leukemia Res. , vol.21 , pp. 997-999
    • Kreitman, R.J.1
  • 70
    • 0024349836 scopus 로고
    • A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin
    • 2498664 1:CAS:528:DyaL1MXktlehtrg%3D 10.1038/339394a0
    • Chaudhary VK, Queen C, Junghans RP, Waldmann TA, FitzGerald DJ, Pastan I. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature. 1989;339:394-7.
    • (1989) Nature , vol.339 , pp. 394-397
    • Chaudhary, V.K.1    Queen, C.2    Junghans, R.P.3    Waldmann, T.A.4    Fitzgerald, D.J.5    Pastan, I.6
  • 71
    • 0028335616 scopus 로고
    • Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions
    • 7910034 1:CAS:528:DyaK2cXivV2mt7Y%3D 10.1021/bi00184a014
    • Reiter Y, Brinkmann U, Kreitman RJ, Jung S-H, Lee B, Pastan I. Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions. Biochemistry. 1994;33:5451-9.
    • (1994) Biochemistry , vol.33 , pp. 5451-5459
    • Reiter, Y.1    Brinkmann, U.2    Kreitman, R.J.3    Jung, S.-H.4    Lee, B.5    Pastan, I.6
  • 72
    • 0029383661 scopus 로고
    • Targeting Pseudomonas exotoxin to hematologic malignancies
    • 8562907 1:CAS:528:DyaK28XitlOgsw%3D%3D 10.1006/scbi.1995.0038
    • Kreitman RJ, Pastan I. Targeting Pseudomonas exotoxin to hematologic malignancies. Semin Cancer Biol. 1995;6:297-306.
    • (1995) Semin. Cancer. Biol. , vol.6 , pp. 297-306
    • Kreitman, R.J.1    Pastan, I.2
  • 73
    • 70350148193 scopus 로고    scopus 로고
    • Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies
    • 19689336 1:CAS:528:DC%2BD1MXptVajsro%3D 10.2174/138161209788923949
    • Kreitman RJ. Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies. Current Pharmaceutical Design. 2009;15:2652-64.
    • (2009) Current Pharmaceutical Design , vol.15 , pp. 2652-2664
    • Kreitman, R.J.1
  • 76
    • 0028867234 scopus 로고
    • Diagnostic relevance of peripheral blood immunocytochemistry in hairy cell leukaemia
    • 8537498 1:STN:280:DyaK287jvVWltw%3D%3D 10.1136/jcp.48.10.955
    • Cordone I, Annino L, Masi S, Pescarmona E, Rahimi S, Ferrari A, et al. Diagnostic relevance of peripheral blood immunocytochemistry in hairy cell leukaemia. J Clin Pathol. 1995;48:955-60.
    • (1995) J Clin Pathol , vol.48 , pp. 955-960
    • Cordone, I.1    Annino, L.2    Masi, S.3    Pescarmona, E.4    Rahimi, S.5    Ferrari, A.6
  • 77
    • 84864144129 scopus 로고    scopus 로고
    • CD22 and Siglec-G in B cell function and tolerance
    • 22677186 1:CAS:528:DC%2BC38Xot12ltbc%3D 10.1016/j.it.2012.04.010
    • Poe JC, Tedder TF. CD22 and Siglec-G in B cell function and tolerance. Trends Immunol. 2012;33:413-20.
    • (2012) Trends Immunol , vol.33 , pp. 413-420
    • Poe, J.C.1    Tedder, T.F.2
  • 78
    • 0032147065 scopus 로고    scopus 로고
    • CD22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor
    • 9695185 1:CAS:528:DyaK1cXltlCiurw%3D 10.1006/smim.1998.0121
    • Sato S, Tuscano JM, Inaoki M, Tedder TF. CD22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor. Semin Immunol. 1998;10:287-97.
    • (1998) Semin Immunol , vol.10 , pp. 287-297
    • Sato, S.1    Tuscano, J.M.2    Inaoki, M.3    Tedder, T.F.4
  • 79
    • 0035210119 scopus 로고    scopus 로고
    • Flow cytometry of peripheral blood and bone marrow cells from patients with hairy cell leukemia: Phenotype of hairy cells, lymphocyte subsets and detection of minimal residual disease after treatment
    • 11845978 1:STN:280:DC%2BD387hsVaisg%3D%3D
    • Babusikova O, Tomova A, Kusenda J, Gyarfas J. Flow cytometry of peripheral blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells, lymphocyte subsets and detection of minimal residual disease after treatment. Neoplasma. 2001;48:350-7.
    • (2001) Neoplasma , vol.48 , pp. 350-357
    • Babusikova, O.1    Tomova, A.2    Kusenda, J.3    Gyarfas, J.4
  • 81
    • 0033047767 scopus 로고    scopus 로고
    • Complete regression of human B cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by Cynomolgus monkeys
    • 10077166 1:CAS:528:DyaK1MXhvVKrs70%3D 10.1002/(SICI)1097-0215(19990331) 81:1<148: AID-IJC24>3.0.CO;2-L
    • Kreitman RJ, Wang QC, FitzGerald DJP, Pastan I. Complete regression of human B cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by Cynomolgus monkeys. Int J Cancer. 1999;81:148-55.
    • (1999) Int. J. Cancer , vol.81 , pp. 148-155
    • Kreitman, R.J.1    Wang, Q.C.2    Fitzgerald, D.J.P.3    Pastan, I.4
  • 82
    • 0034048735 scopus 로고    scopus 로고
    • Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) towards fresh malignant cells from patients with B cell leukemias
    • 10778980 1:CAS:528:DC%2BD3cXjtVOqtLc%3D
    • Kreitman RJ, Margulies I, Stetler-Stevenson M, Wang QC, FitzGerald DJP, Pastan I. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) towards fresh malignant cells from patients with B cell leukemias. Clin Cancer Res. 2000;6:1476-87.
    • (2000) Clin. Cancer Res. , vol.6 , pp. 1476-1487
    • Kreitman, R.J.1    Margulies, I.2    Stetler-Stevenson, M.3    Wang, Q.C.4    Fitzgerald, D.J.P.5    Pastan, I.6
  • 83
    • 0035954624 scopus 로고    scopus 로고
    • Efficacy of the Anti-CD22 Recombinant Immunotoxin BL22 in Chemotherapy-Resistant Hairy-Cell Leukemia
    • 11474661 1:CAS:528:DC%2BD3MXlvVKqs7k%3D 10.1056/NEJM200107263450402
    • Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, FitzGerald DJ, et al. Efficacy of the Anti-CD22 Recombinant Immunotoxin BL22 in Chemotherapy-Resistant Hairy-Cell Leukemia. New Engl J Med. 2001;345:241-7.
    • (2001) New. Engl. J. Med. , vol.345 , pp. 241-247
    • Kreitman, R.J.1    Wilson, W.H.2    Bergeron, K.3    Raggio, M.4    Stetler-Stevenson, M.5    Fitzgerald, D.J.6
  • 84
    • 27244448693 scopus 로고    scopus 로고
    • Phase i trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B cell malignancies
    • 16061911 1:CAS:528:DC%2BD2MXhtFWqsLfI 10.1200/JCO.2005.11.437
    • Kreitman RJ, Squires DR, Stetler-Stevenson M, Noel P, Fitzgerald DJ, Wilson WH, et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B cell malignancies. J Clin Oncol. 2005;23:6719-29.
    • (2005) J Clin Oncol , vol.23 , pp. 6719-6729
    • Kreitman, R.J.1    Squires, D.R.2    Stetler-Stevenson, M.3    Noel, P.4    Fitzgerald, D.J.5    Wilson, W.H.6
  • 85
    • 67649933809 scopus 로고    scopus 로고
    • Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia
    • 19414673 1:CAS:528:DC%2BD1MXoslyisL4%3D 10.1200/JCO.2008.20.2630
    • Kreitman RJ, Stetler-Stevenson M, Margulies I, Noel P, FitzGerald DJP, Wilson WH, et al. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol. 2009;27:2983-90.
    • (2009) J Clin Oncol , vol.27 , pp. 2983-2990
    • Kreitman, R.J.1    Stetler-Stevenson, M.2    Margulies, I.3    Noel, P.4    Fitzgerald, D.J.P.5    Wilson, W.H.6
  • 86
    • 0036554968 scopus 로고    scopus 로고
    • Improved Cytotoxic activity towards cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display
    • 11948105 1:CAS:528:DC%2BD38XjsF2lsbo%3D
    • Salvatore G, Beers R, Margulies I, Kreitman RJ, Pastan I. Improved Cytotoxic activity towards cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clin Cancer Res. 2002;8:995-1002.
    • (2002) Clin Cancer Res , vol.8 , pp. 995-1002
    • Salvatore, G.1    Beers, R.2    Margulies, I.3    Kreitman, R.J.4    Pastan, I.5
  • 87
    • 1642345125 scopus 로고    scopus 로고
    • Induction of Caspase-Dependent Programmed Cell Death in B cell Chronic Lymphocytic Leukemia Cells by Anti-CD22 Immunotoxins
    • 14525789 1:CAS:528:DC%2BD2cXjtVaksLk%3D 10.1182/blood-2003-04-1317
    • Decker T, Oelsner M, Kreitman RJ, Salvatore G, Wang QC, Pastan I, et al. Induction of Caspase-Dependent Programmed Cell Death in B cell Chronic Lymphocytic Leukemia Cells by Anti-CD22 Immunotoxins. Blood. 2004;103:2718-26.
    • (2004) Blood , vol.103 , pp. 2718-2726
    • Decker, T.1    Oelsner, M.2    Kreitman, R.J.3    Salvatore, G.4    Wang, Q.C.5    Pastan, I.6
  • 88
    • 12844267487 scopus 로고    scopus 로고
    • In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin
    • 15491997 1:CAS:528:DC%2BD2MXpslejtrY%3D 10.1074/jbc.M504403200
    • Ho M, Kreitman RJ, Onda M, Pastan I. In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin. J Biol Chem. 2005;280:607-17.
    • (2005) J Biol Chem , vol.280 , pp. 607-617
    • Ho, M.1    Kreitman, R.J.2    Onda, M.3    Pastan, I.4
  • 89
    • 84861542159 scopus 로고    scopus 로고
    • Phase i trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia
    • 22355053 1:CAS:528:DC%2BC38XhtVansbfP 10.1200/JCO.2011.38.1756 Phase I dose-escalation trial of moxetumomab pasudotox in patients with HCL. The agent is now undergoing multicenter pivotal phase III testing
    • •• Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol. 2012;30:1822-8. Phase I dose-escalation trial of moxetumomab pasudotox in patients with HCL. The agent is now undergoing multicenter pivotal phase III testing.
    • (2012) J Clin Oncol , vol.30 , pp. 1822-1828
    • Kreitman, R.J.1    Tallman, M.S.2    Robak, T.3    Coutre, S.4    Wilson, W.H.5    Stetler-Stevenson, M.6
  • 90
    • 79959293462 scopus 로고    scopus 로고
    • BRAF mutations in hairy-cell leukemia
    • 21663470 1:CAS:528:DC%2BC3MXns12it78%3D 10.1056/NEJMoa1014209 First report showing that BRAF V600E is found in 100 % of HCL compared to 0 % of other hematologic malignancies. This driving mutation is considered to be of etiologic importance in addition to diagnostic utility, and is a target for V600E-directed agents
    • •• Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;364:2305-15. First report showing that BRAF V600E is found in 100 % of HCL compared to 0 % of other hematologic malignancies. This driving mutation is considered to be of etiologic importance in addition to diagnostic utility, and is a target for V600E-directed agents.
    • (2011) N Engl J Med , vol.364 , pp. 2305-2315
    • Tiacci, E.1    Trifonov, V.2    Schiavoni, G.3    Holmes, A.4    Kern, W.5    Martelli, M.P.6
  • 91
    • 84873819555 scopus 로고    scopus 로고
    • Which drug, and when, for patients with BRAF-mutant melanoma?
    • 23369684 1:CAS:528:DC%2BC3sXhvFSksrg%3D 10.1016/S1470-2045(12)70539-9
    • Jang S, Atkins MB. Which drug, and when, for patients with BRAF-mutant melanoma? Lancet Oncol. 2013;14:e60-9.
    • (2013) Lancet Oncol , vol.14 , pp. 60-69
    • Jang, S.1    Atkins, M.B.2
  • 92
    • 18444374405 scopus 로고    scopus 로고
    • Mutations of the BRAF gene in human cancer
    • 12068308 1:CAS:528:DC%2BD38XkvVagsLo%3D 10.1038/nature00766
    • Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-54.
    • (2002) Nature , vol.417 , pp. 949-954
    • Davies, H.1    Bignell, G.R.2    Cox, C.3    Stephens, P.4    Edkins, S.5    Clegg, S.6
  • 93
    • 0036894746 scopus 로고    scopus 로고
    • BRAF and RAS mutations in human lung cancer and melanoma
    • 12460918 1:CAS:528:DC%2BD38XpsVahsbo%3D
    • Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002;62:6997-7000.
    • (2002) Cancer Res , vol.62 , pp. 6997-7000
    • Brose, M.S.1    Volpe, P.2    Feldman, M.3    Kumar, M.4    Rishi, I.5    Gerrero, R.6
  • 94
    • 0037657499 scopus 로고    scopus 로고
    • Regulation of hairy-cell survival through constitutive activation of mitogen-activated protien kinase pathways
    • 12700663 1:CAS:528:DC%2BD3sXivFGktLw%3D 10.1038/sj.onc.1206398
    • Kamiguti AS, Harris RJ, Slupsky JR, Baker PK, Cawley JC, Zuzel M, et al. Regulation of hairy-cell survival through constitutive activation of mitogen-activated protien kinase pathways. Oncogene. 2003;22:2272-84.
    • (2003) Oncogene , vol.22 , pp. 2272-2284
    • Kamiguti, A.S.1    Harris, R.J.2    Slupsky, J.R.3    Baker, P.K.4    Cawley, J.C.5    Zuzel, M.6
  • 95
    • 81155148175 scopus 로고    scopus 로고
    • High resolution melting analysis for detection of BRAF exon 15 mutations in hairy cell leukaemia and other lymphoid malignancies
    • 21910720 1:CAS:528:DC%2BC38XhtVGjs7w%3D 10.1111/j.1365-2141.2011.08868.x
    • Boyd EM, Bench AJ, van Veer MB, Wright P, Bloxham DM, Follows GA, et al. High resolution melting analysis for detection of BRAF exon 15 mutations in hairy cell leukaemia and other lymphoid malignancies. Br J Haematol. 2011;155:609-12.
    • (2011) Br J Haematol , vol.155 , pp. 609-612
    • Boyd, E.M.1    Bench, A.J.2    Van Veer, M.B.3    Wright, P.4    Bloxham, D.M.5    Follows, G.A.6
  • 96
    • 84860593139 scopus 로고    scopus 로고
    • Detection of BRAF mutations in patients with hairy cell leukemia and related lymphoproliferative disorders
    • 22133769 1:CAS:528:DC%2BC38Xhs1ajs7%2FF 10.3324/haematol.2011.054874
    • Blombery PA, Wong SQ, Hewitt CA, Dobrovic A, Maxwell EL, Juneja S, et al. Detection of BRAF mutations in patients with hairy cell leukemia and related lymphoproliferative disorders. Haematologica. 2012;97:780-3.
    • (2012) Haematologica , vol.97 , pp. 780-783
    • Blombery, P.A.1    Wong, S.Q.2    Hewitt, C.A.3    Dobrovic, A.4    Maxwell, E.L.5    Juneja, S.6
  • 97
    • 67649908511 scopus 로고    scopus 로고
    • Implementation of novel pyrosequencing assays to screen for common mutations of BRAF and KRAS in a cohort of sporadic colorectal cancers
    • 19430299 1:CAS:528:DC%2BD1MXmt1artb0%3D 10.1097/PDM.0b013e318182af52
    • Packham D, Ward RL, Ap Lin V, Hawkins NJ, Hitchins MP. Implementation of novel pyrosequencing assays to screen for common mutations of BRAF and KRAS in a cohort of sporadic colorectal cancers. Diagn Mol Pathol. 2009;18:62-71.
    • (2009) Diagn Mol Pathol , vol.18 , pp. 62-71
    • Packham, D.1    Ward, R.L.2    Ap Lin, V.3    Hawkins, N.J.4    Hitchins, M.P.5
  • 98
    • 43249116705 scopus 로고    scopus 로고
    • Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing
    • 18408729 1:CAS:528:DC%2BD1cXlsFCmsrw%3D 10.1038/nm1708
    • Li J, Wang L, Mamon H, Kulke MH, Berbeco R, Makrigiorgos GM. Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. Nat Med. 2008;14:579-84.
    • (2008) Nat Med , vol.14 , pp. 579-584
    • Li, J.1    Wang, L.2    Mamon, H.3    Kulke, M.H.4    Berbeco, R.5    Makrigiorgos, G.M.6
  • 99
    • 84859576293 scopus 로고    scopus 로고
    • Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation
    • 22210875 1:CAS:528:DC%2BC38XlslyjsLs%3D 10.1182/blood-2011-09-379339 First demonstration that HCL cases immunophenotypically consistent with classic HCL, but expressing the IGHV4-34 immunoglobulin rearrangement, are wild-type for BRAF
    • • Xi L, Arons E, Navarro W, Calvo KR, Stetler-Stevenson M, Raffeld M, et al. Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. Blood. 2012;119:3330-2. First demonstration that HCL cases immunophenotypically consistent with classic HCL, but expressing the IGHV4-34 immunoglobulin rearrangement, are wild-type for BRAF.
    • (2012) Blood , vol.119 , pp. 3330-3332
    • Xi, L.1    Arons, E.2    Navarro, W.3    Calvo, K.R.4    Stetler-Stevenson, M.5    Raffeld, M.6
  • 100
    • 84864219291 scopus 로고    scopus 로고
    • Rapid detection and quantitation of BRAF mutations in hairy cell leukemia using a sensitive pyrosequencing assay
    • 22706871 1:CAS:528:DC%2BC38XhtF2jsr7I 10.1309/AJCPL0OPXI9LZITV
    • Verma S, Greaves WO, Ravandi F, Reddy N, Bueso-Ramos CE, O'Brien S, et al. Rapid detection and quantitation of BRAF mutations in hairy cell leukemia using a sensitive pyrosequencing assay. Am J Clin Pathol. 2012;138:153-6.
    • (2012) Am J Clin Pathol , vol.138 , pp. 153-156
    • Verma, S.1    Greaves, W.O.2    Ravandi, F.3    Reddy, N.4    Bueso-Ramos, C.E.5    O'Brien, S.6
  • 101
    • 84869232543 scopus 로고    scopus 로고
    • Investigation of the BRAF V600E mutation by pyrosequencing in lymphoproliferative disorders
    • 23161722 10.1309/AJCP5TWORA0TMXGL
    • Laurini JA, Aoun P, Iqbal J, Chan W, Greiner TC. Investigation of the BRAF V600E mutation by pyrosequencing in lymphoproliferative disorders. Am J Clin Pathol. 2012;138:877-83.
    • (2012) Am J Clin Pathol , vol.138 , pp. 877-883
    • Laurini, J.A.1    Aoun, P.2    Iqbal, J.3    Chan, W.4    Greiner, T.C.5
  • 102
    • 84859216321 scopus 로고    scopus 로고
    • Pyrosequencing of BRAF V600E in routine samples of hairy cell leukaemia identifies CD5+ variant hairy cell leukaemia that lacks V600E
    • 22145942 1:CAS:528:DC%2BC38XmvFGnsrk%3D 10.1111/j.1365-2141.2011.08963.x
    • Lennerz JK, Klaus BM, Marienfeld RB, Moller P. Pyrosequencing of BRAF V600E in routine samples of hairy cell leukaemia identifies CD5+ variant hairy cell leukaemia that lacks V600E. Br J Haematol. 2012;157:267-9.
    • (2012) Br J Haematol , vol.157 , pp. 267-269
    • Lennerz, J.K.1    Klaus, B.M.2    Marienfeld, R.B.3    Moller, P.4
  • 103
    • 84855590382 scopus 로고    scopus 로고
    • The BRAF V600E mutation in hairy cell leukemia and other mature B cell neoplasms
    • 22072557 1:CAS:528:DC%2BC38XpvFGruw%3D%3D 10.1182/blood-2011-08-368209
    • Arcaini L, Zibellini S, Boveri E, Riboni R, Rattotti S, Varettoni M, et al. The BRAF V600E mutation in hairy cell leukemia and other mature B cell neoplasms. Blood. 2012;119:188-91.
    • (2012) Blood , vol.119 , pp. 188-191
    • Arcaini, L.1    Zibellini, S.2    Boveri, E.3    Riboni, R.4    Rattotti, S.5    Varettoni, M.6
  • 104
    • 84855597743 scopus 로고    scopus 로고
    • Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation
    • 22028477 1:CAS:528:DC%2BC38XpvFGqsg%3D%3D 10.1182/blood-2011-08-371179
    • Tiacci E, Schiavoni G, Forconi F, Santi A, Trentin L, Ambrosetti A, et al. Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. Blood. 2012;119:192-5.
    • (2012) Blood , vol.119 , pp. 192-195
    • Tiacci, E.1    Schiavoni, G.2    Forconi, F.3    Santi, A.4    Trentin, L.5    Ambrosetti, A.6
  • 105
    • 84862894512 scopus 로고    scopus 로고
    • Correlation of the BRAF V600E mutation in hairy cell leukaemia with morphology, cytochemistry and immunophenotype
    • 22313586 1:STN:280:DC%2BC38vitlSntA%3D%3D 10.1111/j.1751-553X.2012.01402. x
    • Langabeer SE, O'Brien D, Liptrot S, Flynn CM, Hayden PJ, Conneally E, et al. Correlation of the BRAF V600E mutation in hairy cell leukaemia with morphology, cytochemistry and immunophenotype. International Journal of Laboratory Hematology. 2012;34:417-21.
    • (2012) International Journal of Laboratory Hematology , vol.34 , pp. 417-421
    • Langabeer, S.E.1    O'Brien, D.2    Liptrot, S.3    Flynn, C.M.4    Hayden, P.J.5    Conneally, E.6
  • 107
    • 84861739190 scopus 로고    scopus 로고
    • Real-time PCR-based analysis of BRAF V600E mutation in low and intermediate grade lymphomas confirms frequent occurrence in hairy cell leukaemia
    • 22246856 1:CAS:528:DC%2BC38XhvVCisb%2FE 10.1002/hon.1023
    • Ewalt M, Nandula S, Phillips A, Alobeid B, Murty VV, Mansukhani MM, et al. Real-time PCR-based analysis of BRAF V600E mutation in low and intermediate grade lymphomas confirms frequent occurrence in hairy cell leukaemia. Hematol Oncol. 2012;30:190-3.
    • (2012) Hematol Oncol , vol.30 , pp. 190-193
    • Ewalt, M.1    Nandula, S.2    Phillips, A.3    Alobeid, B.4    Murty, V.V.5    Mansukhani, M.M.6
  • 108
    • 84859355494 scopus 로고    scopus 로고
    • Development and validation of a real-time quantification assay to detect and monitor BRAFV600E mutations in hairy cell leukemia
    • 22331186 1:CAS:528:DC%2BC38Xlt1OrsL8%3D 10.1182/blood-2011-10-383323
    • Schnittger S, Bacher U, Haferlach T, Wendland N, Ulke M, Dicker F, et al. Development and validation of a real-time quantification assay to detect and monitor BRAFV600E mutations in hairy cell leukemia. Blood. 2012;119:3151-4.
    • (2012) Blood , vol.119 , pp. 3151-3154
    • Schnittger, S.1    Bacher, U.2    Haferlach, T.3    Wendland, N.4    Ulke, M.5    Dicker, F.6
  • 110
    • 84868381842 scopus 로고    scopus 로고
    • Absence of BRAF V600E mutation in hematologic malignancies excluding hairy-cell leukemia
    • 22639828 1:CAS:528:DC%2BC38Xhs1ars7zN 10.3109/10428194.2012.695777
    • Ping N, Wang Q, Wang Q, Dong S, Wu L, Xue Y, et al. Absence of BRAF V600E mutation in hematologic malignancies excluding hairy-cell leukemia. Leuk Lymphoma. 2012;53:2498-9.
    • (2012) Leuk Lymphoma , vol.53 , pp. 2498-2499
    • Ping, N.1    Wang, Q.2    Wang, Q.3    Dong, S.4    Wu, L.5    Xue, Y.6
  • 111
    • 84870067191 scopus 로고    scopus 로고
    • Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia
    • 22531170 10.1097/PAS.0b013e3182549b50
    • Andrulis M, Penzel R, Weichert W, von Deimling A, Capper D. Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia. Am J Surg Pathol. 2012;36:1796-800.
    • (2012) Am J Surg Pathol , vol.36 , pp. 1796-1800
    • Andrulis, M.1    Penzel, R.2    Weichert, W.3    Von Deimling, A.4    Capper, D.5
  • 113
    • 79951494668 scopus 로고    scopus 로고
    • Initial genome sequencing and analysis of multiple myeloma
    • 21430775 1:CAS:528:DC%2BC3MXjvVOisLY%3D 10.1038/nature09837
    • Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011;471:467-72.
    • (2011) Nature , vol.471 , pp. 467-472
    • Chapman, M.A.1    Lawrence, M.S.2    Keats, J.J.3    Cibulskis, K.4    Sougnez, C.5    Schinzel, A.C.6
  • 114
    • 0037379904 scopus 로고    scopus 로고
    • High prevalence of BRAF mutations in thyroid cancer: Genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma
    • 12670889 1:CAS:528:DC%2BD3sXisFaisLs%3D
    • Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63:1454-7.
    • (2003) Cancer Res , vol.63 , pp. 1454-1457
    • Kimura, E.T.1    Nikiforova, M.N.2    Zhu, Z.3    Knauf, J.A.4    Nikiforov, Y.E.5    Fagin, J.A.6
  • 115
    • 84055222114 scopus 로고    scopus 로고
    • Role of BRAF in thyroid oncogenesis
    • 21900390 1:CAS:528:DC%2BC3MXhs1CqtrvL 10.1158/1078-0432.CCR-11-1155
    • Caronia LM, Phay JE, Shah MH. Role of BRAF in thyroid oncogenesis. Clin Cancer Res. 2011;17:7511-7.
    • (2011) Clin Cancer Res , vol.17 , pp. 7511-7517
    • Caronia, L.M.1    Phay, J.E.2    Shah, M.H.3
  • 116
    • 73949094832 scopus 로고    scopus 로고
    • BRAF mutation status in gastrointestinal stromal tumors
    • 20023270 1:CAS:528:DC%2BC3cXhtF2ltrk%3D 10.1309/AJCPPCKGA2QGBJ1R
    • Hostein I, Faur N, Primois C, Boury F, Denard J, Emile JF, et al. BRAF mutation status in gastrointestinal stromal tumors. Am J Clin Pathol. 2010;133:141-8.
    • (2010) Am J Clin Pathol , vol.133 , pp. 141-148
    • Hostein, I.1    Faur, N.2    Primois, C.3    Boury, F.4    Denard, J.5    Emile, J.F.6
  • 117
    • 79952609650 scopus 로고    scopus 로고
    • Histopathological and molecular features of late relapses in non-seminomas
    • 20955261 10.1111/j.1464-410X.2010.09631.x
    • Mayer F, Wermann H, Albers P, Stoop H, Gillis AJ, Hartmann JT, et al. Histopathological and molecular features of late relapses in non-seminomas. BJU Int. 2011;107:936-43.
    • (2011) BJU Int , vol.107 , pp. 936-943
    • Mayer, F.1    Wermann, H.2    Albers, P.3    Stoop, H.4    Gillis, A.J.5    Hartmann, J.T.6
  • 118
    • 65549094095 scopus 로고    scopus 로고
    • Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors
    • 19289622 1:CAS:528:DC%2BD1MXlvFOgsrs%3D 10.1200/JCO.2008.18.8623
    • Honecker F, Wermann H, Mayer F, Gillis AJ, Stoop H, van Gurp RJ, et al. Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors. J Clin Oncol. 2009;27:2129-36.
    • (2009) J Clin Oncol , vol.27 , pp. 2129-2136
    • Honecker, F.1    Wermann, H.2    Mayer, F.3    Gillis, A.J.4    Stoop, H.5    Van Gurp, R.J.6
  • 119
    • 84857942952 scopus 로고    scopus 로고
    • Discovery and prioritization of somatic mutations in diffuse large B cell lymphoma (DLBCL) by whole-exome sequencing
    • 22343534 1:CAS:528:DC%2BC38XjvFymt7s%3D 10.1073/pnas.1121343109
    • Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, Sougnez C, et al. Discovery and prioritization of somatic mutations in diffuse large B cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A. 2012;109:3879-84.
    • (2012) Proc Natl Acad Sci U S A , vol.109 , pp. 3879-3884
    • Lohr, J.G.1    Stojanov, P.2    Lawrence, M.S.3    Auclair, D.4    Chapuy, B.5    Sougnez, C.6
  • 120
    • 70349432298 scopus 로고    scopus 로고
    • Molecular analysis of PIK3CA, BRAF, and RAS oncogenes in periampullary and ampullary adenomas and carcinomas
    • 19440799 10.1007/s11605-009-0917-4
    • Schonleben F, Qiu W, Allendorf JD, Chabot JA, Remotti HE, Su GH. Molecular analysis of PIK3CA, BRAF, and RAS oncogenes in periampullary and ampullary adenomas and carcinomas. J Gastrointest Surg. 2009;13:1510-6.
    • (2009) J Gastrointest Surg , vol.13 , pp. 1510-1516
    • Schonleben, F.1    Qiu, W.2    Allendorf, J.D.3    Chabot, J.A.4    Remotti, H.E.5    Su, G.H.6
  • 121
    • 79953309255 scopus 로고    scopus 로고
    • Genetics and epigenetics of small bowel adenocarcinoma: The interactions of CIN, MSI, and CIMP
    • 21297586 1:CAS:528:DC%2BC3MXktFGjtLo%3D 10.1038/modpathol.2010.223
    • Warth A, Kloor M, Schirmacher P, Blaker H. Genetics and epigenetics of small bowel adenocarcinoma: the interactions of CIN, MSI, and CIMP. Mod Pathol. 2011;24:564-70.
    • (2011) Mod Pathol , vol.24 , pp. 564-570
    • Warth, A.1    Kloor, M.2    Schirmacher, P.3    Blaker, H.4
  • 122
    • 79954441895 scopus 로고    scopus 로고
    • Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma
    • 21274720 1:CAS:528:DC%2BC3MXhvVyrsrk%3D 10.1007/s00401-011-0802-6
    • Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 2011;121:397-405.
    • (2011) Acta Neuropathol , vol.121 , pp. 397-405
    • Schindler, G.1    Capper, D.2    Meyer, J.3    Janzarik, W.4    Omran, H.5    Herold-Mende, C.6
  • 123
    • 79959795786 scopus 로고    scopus 로고
    • Improved survival with vemurafenib in melanoma with BRAF V600E mutation
    • 21639808 1:CAS:528:DC%2BC3MXosVeitbs%3D 10.1056/NEJMoa1103782
    • Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-16.
    • (2011) N Engl J Med , vol.364 , pp. 2507-2516
    • Chapman, P.B.1    Hauschild, A.2    Robert, C.3    Haanen, J.B.4    Ascierto, P.5    Larkin, J.6
  • 124
    • 84855179546 scopus 로고    scopus 로고
    • Vemurafenib for melanoma metastases to the brain
    • 22188003 1:CAS:528:DC%2BC38XmvVKhsA%3D%3D 10.1056/NEJMc1111672
    • Rochet NM, Kottschade LA, Markovic SN. Vemurafenib for melanoma metastases to the brain. N Engl J Med. 2011;365:2439-41.
    • (2011) N Engl J Med , vol.365 , pp. 2439-2441
    • Rochet, N.M.1    Kottschade, L.A.2    Markovic, S.N.3
  • 126
    • 84861417677 scopus 로고    scopus 로고
    • BRAF inhibition in refractory hairy-cell leukemia
    • 22621641 10.1056/NEJMc1202124 First report showing efficacy of Vemurafenib targeting V600E in HCL
    • •• Dietrich S, Glimm H, Andrulis M, von Kalle C, Ho AD, Zenz T. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med. 2012;366:2038-40. First report showing efficacy of Vemurafenib targeting V600E in HCL.
    • (2012) N Engl J Med , vol.366 , pp. 2038-2040
    • Dietrich, S.1    Glimm, H.2    Andrulis, M.3    Von Kalle, C.4    Ho, A.D.5    Zenz, T.6
  • 128
    • 84875055512 scopus 로고    scopus 로고
    • Rapid response of biallelic BRAF V600E mutated hairy cell leukaemia to low dose vemurafenib
    • 23278307 1:CAS:528:DC%2BC3sXktFKnt70%3D 10.1111/bjh.12201
    • Follows GA, Sims H, Bloxham DM, Zenz T, Hopper MA, Liu H, et al. Rapid response of biallelic BRAF V600E mutated hairy cell leukaemia to low dose vemurafenib. Br J Haematol. 2013;161:150-3.
    • (2013) Br J Haematol , vol.161 , pp. 150-153
    • Follows, G.A.1    Sims, H.2    Bloxham, D.M.3    Zenz, T.4    Hopper, M.A.5    Liu, H.6
  • 129
    • 84875340204 scopus 로고    scopus 로고
    • Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation
    • 23300174 10.3324/haematol.2012.082404
    • Peyrade F, Re D, Ginet C, Gastaud L, Allegra M, Ballotti R, et al. Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation. Haematologica. 2013;98:e20-2.
    • (2013) Haematologica , vol.98 , pp. 20-22
    • Peyrade, F.1    Re, D.2    Ginet, C.3    Gastaud, L.4    Allegra, M.5    Ballotti, R.6
  • 130
    • 84864285704 scopus 로고    scopus 로고
    • Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial
    • 22735384 1:CAS:528:DC%2BC38Xpt1SgtLg%3D 10.1016/S0140-6736(12)60868-X
    • Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358-65.
    • (2012) Lancet , vol.380 , pp. 358-365
    • Hauschild, A.1    Grob, J.J.2    Demidov, L.V.3    Jouary, T.4    Gutzmer, R.5    Millward, M.6
  • 131
    • 84863673204 scopus 로고    scopus 로고
    • Improved survival with MEK inhibition in BRAF-mutated melanoma
    • 22663011 1:CAS:528:DC%2BC38XhtFKjs7zN 10.1056/NEJMoa1203421
    • Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367:107-14.
    • (2012) N Engl J Med , vol.367 , pp. 107-114
    • Flaherty, K.T.1    Robert, C.2    Hersey, P.3    Nathan, P.4    Garbe, C.5    Milhem, M.6
  • 132
    • 84877092892 scopus 로고    scopus 로고
    • Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma
    • 23444215 1:CAS:528:DC%2BC3sXlvFyjtro%3D 10.1158/1078-0432.CCR-12-3476
    • Catalanotti F, Solit DB, Pulitzer MP, Berger MF, Scott SN, Iyriboz T, et al. Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma. Clin Cancer Res. 2013;19:2257-64.
    • (2013) Clin Cancer Res , vol.19 , pp. 2257-2264
    • Catalanotti, F.1    Solit, D.B.2    Pulitzer, M.P.3    Berger, M.F.4    Scott, S.N.5    Iyriboz, T.6
  • 133
    • 84868224906 scopus 로고    scopus 로고
    • Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
    • 23020132 1:CAS:528:DC%2BC38Xhs1eksLrJ 10.1056/NEJMoa1210093
    • Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367:1694-703.
    • (2012) N Engl J Med , vol.367 , pp. 1694-1703
    • Flaherty, K.T.1    Infante, J.R.2    Daud, A.3    Gonzalez, R.4    Kefford, R.F.5    Sosman, J.6
  • 134
    • 84989931315 scopus 로고    scopus 로고
    • Ibrutinib in CLL and B Cell Malignancies
    • Brown JR. Ibrutinib in CLL and B Cell Malignancies. Leuk Lymphoma 2013.
    • (2013) Leuk Lymphoma
    • Brown, J.R.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.